Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing treatments primarily for rare and orphan diseases. Headquartered in Torrance, California, the company offers Endari, an oral pharmaceutical grade L-glutamine treatment designed to reduce acute complications of sickle cell disease in patients aged five years and older. In addition to Endari, Emmaus provides NutreStore, an L-glutamine powder, and AminoPure, a nutritional supplement. The company is also engaged in developing therapeutic products utilizing cell sheet technology for corneal diseases, alongside efforts to create a pharmaceutical-grade L-glutamine oral powder aimed at treating diverticulosis. Founded in 2000, Emmaus Life Sciences was formerly known as Emmaus Holdings, Inc. before adopting its current name in September 2011.